Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on August 4, 2022. The report details corporate governance changes approved by the Board of Directors on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The authorized number of directors was increased from eight (8) to ten (10).
- New Appointments: William J. Peters (CFO) and Jacob Liawatidewi (EVP of Corporate Administration Center, Sales and Marketing) were appointed as Class I directors, effective immediately.
- Independence Determination: The Board determined that Diane G. Gerst is independent, resulting in six of the current directors being classified as independent under Nasdaq listing standards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation, the Company stated that no changes were made to the existing compensatory arrangements for the New Directors. Background information on the new directors was previously disclosed in the Proxy Statement on Form DEF 14A filed on April 14, 2022.
Investor Verification Checklist
- Verify the independence status of the six directors as determined by the Board.
- Review the Proxy Statement on Form DEF 14A (filed April 14, 2022) for detailed biographical and conflict-of-interest information regarding William J. Peters and Jacob Liawatidewi.
- Confirm the term length for the new Class I directors (until the 2023 annual meeting of stockholders).